Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 2/2012

01-02-2012 | Original Paper

Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis

Authors: Olivia Keiser, Ben Spycher, Andri Rauch, Alexandra Calmy, Matthias Cavassini, Tracy R. Glass, Dunja Nicca, Bruno Ledergerber, Matthias Egger, The Swiss HIV Cohort Study

Published in: AIDS and Behavior | Issue 2/2012

Login to get access

Abstract

An in-depth understanding of the different groups that make up the HIV-infected population should inform prevention and care. Using latent class analysis (LCA) we identified seven groups with similar socio-demographic and behavioral characteristics at enrolment in the Swiss HIV Cohort Study: older gay men, younger gay men, older heterosexual men, injection drug users, single migrants, migrant women in partnerships and heterosexual men and women. Outcomes of combination antiretroviral therapy (ART) were analyzed in 1,633 patients starting ART. Compared to older gay men, the probability of a virologic response to ART was reduced in single migrants, in older heterosexual men and in IDUs. Loss to follow-up was higher in single migrants and IDUs, and mortality was increased in older heterosexual men and IDUs. Socio-behavioral groups identified by LCA allow insights above what can be gleaned from traditional transmission groups, and may identify patients who could benefit from targeted interventions.
Literature
1.
May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368(9534):451–8.PubMedCrossRef
2.
Keiser O, Taffe P, Zwahlen M, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS. 2004;18(13):1835–43.PubMedCrossRef
3.
Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 2009;38(6):1624–33.PubMedCrossRef
4.
Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353(9156):863–8.PubMedCrossRef
5.
Pellmar TC, Brandt EN Jr, Baird MA. Health and behavior: the interplay of biological, behavioral, and social influences: summary of an institute of medicine report. Am J Health Promot. 2002;16(4):206–19.PubMedCrossRef
6.
Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.PubMedCrossRef
7.
Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMed
8.
Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231–41.PubMedCrossRef
9.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.PubMedCrossRef
10.
McMahon J, Wanke CA, Terrin N, Skinner S, Knox T. Poverty, hunger, education, and residential status impact survival in HIV. Aids Behavior. 2010. (in press).
11.
Hogg R, Strathdee SA, Craib KJ, O’Shaughnessy MV, Montaner JS, Schechter MT. Lower socioeconomic status and shorter survival following HIV infection. Lancet. 1994;344(8939):1100–1.
12.
Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333(12):751–6.PubMedCrossRef
13.
Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Frei CR. Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies. J Natl Med Assoc. 2009;101(12):122–9.
14.
McDavid Harrison K, Ling Q, Song R, Hall HI. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008;18(12):919–27.PubMedCrossRef
15.
Katz MH, Hsu L, Lingo M, Woelffer G, Schwarcz SK. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol. 1998;148(3):282–91.PubMed
16.
Lazarsfeld R, Henry NW. Latent structure analysis. Latent structure analysis. Boston: Houghton Mifflin; 1968.
17.
Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J. 2008;31(5):974–81.PubMedCrossRef
18.
Ganesalingam J, Stahl D, Wijesekera L, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One. 2009;4(9):e7107.PubMedCrossRef
19.
Girardi E, Angeletti C, Puro V, et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill. 2009;14(43):1–9.
20.
Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5):1179–89.PubMedCrossRef
21.
Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009;10(7):407–16.PubMedCrossRef
22.
Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1–20.
23.
McLachlan G, Peel D. Finite mixture models. New York: John Wiley & Sons; 2000.CrossRef
24.
Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.CrossRef
25.
Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study. AIDS. 1998;12(10):1195–201.PubMedCrossRef
26.
Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.PubMedCrossRef
27.
Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54(2):197–203.PubMed
28.
Greenland S, Gago-Dominguez M, Castelao JE. The value of risk-factor (“black-box”) epidemiology. Epidemiology. 2004;15(5):529–35.PubMedCrossRef
29.
Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63.PubMedCrossRef
30.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.PubMedCrossRef
31.
Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.PubMedCrossRef
32.
Braude HD. Clinical intuition versus statistics: different modes of tacit knowledge in clinical epidemiology and evidence-based medicine. Theor Med Bioeth. 2009;30(3):181–98.PubMedCrossRef
33.
34.
Young J, De Geest S, Spirig R, et al. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV Cohort Study. BMJ. 2004;328(7430):15.PubMedCrossRef
35.
Braitstein P, Brinkhof MWG, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–24.PubMedCrossRef
36.
Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007;12(1):89–96.PubMed
37.
Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther. 2007;12(6):841–51.PubMed
38.
Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med. 2008;9(6):397–405.PubMedCrossRef
39.
Nellen JF, Wit FW, de Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr. 2004;36:943–50.PubMedCrossRef
40.
van den Berg JB, Hak E, Vervoort SC, et al. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med. 2005;6(5):299–306.PubMedCrossRef
41.
World Health Organization. National AIDS programme management. Module 4. Targeted HIV prevention and care interventions. 2007.
42.
Staehelin C, Egloff N, Rickenbach M, Kopp C, Furrer H. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. AIDS Patient Care STDS. 2004;18(11):665–75.PubMedCrossRef
Metadata
Title
Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis
Authors
Olivia Keiser
Ben Spycher
Andri Rauch
Alexandra Calmy
Matthias Cavassini
Tracy R. Glass
Dunja Nicca
Bruno Ledergerber
Matthias Egger
The Swiss HIV Cohort Study
Publication date
01-02-2012
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2012
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9971-5

Other articles of this Issue 2/2012

AIDS and Behavior 2/2012 Go to the issue

Original Paper

Electronic Medical Records and Same Day Patient Tracing Improves Clinic Efficiency and Adherence to Appointments in a Community Based HIV/AIDS Care Program, in Uganda

Original Paper

Concurrent Partnerships, Acute Infection and HIV Epidemic Dynamics Among Young Adults in Zimbabwe

Original Paper

A Brief Assessment of Learning for Orphaned and Abandoned Children in Low and Middle Income Countries

Brief Report

Provider Beliefs and Practices Relating to Tobacco Use in Patients Living with HIV/AIDS: A National Survey

Original Paper

Real-Time Electronic Adherence Monitoring is Feasible, Comparable to Unannounced Pill Counts, and Acceptable

Original Paper

Statistical Challenges in Studying Complex and Changing Families
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits